Biotia, founded at the Jacobs Technion-Cornell Institute Runway Startup Postdoc Program, announced a $2.4 million seed round led by Falcon III Ventures.
Biotia is a health tech company that leverages next-generation DNA sequencing (NGS) and artificial intelligence (AI) software to help hospitals detect and diagnose infectious diseases.
According to a release issued by the company, “The funds will be used to further develop and implement Biotia’s diagnostic testing methods, including its AI-based software Chelsea™, offer myriad advantages over the current approaches in hospitals, such as limited PCR panels or culturing.”
